Clinical trials: Palmoplantar Psoriasis
Psoriasis
Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.
- Trial name
- NCT03135548
- Testing
- Spesolimab (low dose), Spesolimab (high dose)
- Where
- 18 sites in Canada, Denmark and 4 more
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis…
- Trial name
- NCT07013201
- Testing
- Delgocitinib cream, Vehicle cream
- Where
- 40 sites in United States, Canada and 3 more
- Volunteers
- 135 people
- Sponsor
- LEO Pharma
Palmoplantar Pustulosis (PPP)
A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis
What's the problem? Palmoplantar pustulosis (PPP) is a long-term skin condition that mainly affects the palms of hands and soles of feet.
- Trial name
- NCT07270003
- Testing
- Ivarmacitinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital
Palmoplantar Pustulosis
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab.
- Trial name
- NCT04493424
- Testing
- Spesolimab
- Where
- 66 sites in United States, Australia and 12 more
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Pustular Psoriasis (PP)
International Rare And Severe Psoriasis Expert Network
This registry is a prospective observational study in order to describe primarily the natural course of PP subtypes and to gain detailed information about their phenotype.
- Trial name
- IRASPEN (NCT04359394)
- Testing
- biological sampling, Phenotypic description, Photography
- Where
- 8 sites in Germany, Italy and 4 more
- Volunteers
- 180 people
- Sponsor
- University Hospital, Basel, Switzerland
Psoriasis
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
The purpose of this study is to evaluate the efficacy of guselkumab for the treatment of palmoplantar psoriasis.
- Trial name
- G-PLUS (NCT03998683)
- Testing
- Guselkumab 100 mg
- Where
- 26 sites in France, Germany and 3 more
- Volunteers
- 117 people
- Sponsor
- Janssen-Cilag Ltd.
Palmoplantaris Pustulosis
A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis
The purpose of this study is to assess the efficacy, safety, and tolerability of CNTO 1959 following subcutaneous administration in participants with palmoplantar pustulosis.
- Trial name
- NCT01845987
- Testing
- CNTO 1959
- Where
- 8 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Janssen Pharmaceutical K.K.
Psoriasis
Combined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis
To assess whether adding fractional laser to topical corticosteroid improves treatment outcomes in palmoplanter psoriasis compared to topical corticosteroid alone.
- Trial name
- NCT07713212
- Testing
- Fractional CO2 laser assisted drug delivery, Topical Corticosteroid (TCS)
- Where
- Egypt
- Volunteers
- 32 people
- Sponsor
- Cairo University
Palmoplantar Pustulosis
An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
The purpose of this study is to evaluate the efficacy and safety of guselkumab for the treatment of participants with palmoplantar pustulosis.
- Trial name
- NCT02641730
- Testing
- Guselkumab
- Where
- 32 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Janssen Pharmaceutical K.K.
Palmoplantar Pustulosis, Generalized Pustular Psoriasis
Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
This study plans to calculate the prevalence and incidence of palmoplantar pustulosis and generalized pustular psoriasis based on the national medical insurance data and analyze the composition characteristics and some clinical…
- Trial name
- NCT04566471
- Testing
- prevalence/incidence
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Psoriasis, Skin or Nails
Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles
Psoriasis is a common skin disease that can affect 1-3% of the population. For more severe psoriasis, oral medication such as acitretin is sometimes given.
- Trial name
- NCT02181790
- Testing
- Excimer laser, Acitretin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Moderate to Severe Palmoplantar Psoriasis
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Purpose of the study was to demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess the long term efficacy, safety and tolerability of secukinumab.
- Trial name
- GESTURE (NCT01806597)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 54 sites in United States, Australia and 13 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau
Anakinra for Inflammatory Pustular Skin Diseases
Background: Inflammatory pustular skin diseases are a type of autoinflammatory disease in which the immune system attacks the bodys tissues.
- Conditions
- Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
- Trial name
- NCT01794117
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Psoriasis
Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
Subjects with psoriasis will receive intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 (induction therapy) to evaluate the efficacy of infliximab at Week 18.
- Trial name
- TIPS (NCT00686686)
- Testing
- Infliximab
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Palmoplantar Psoriasis, Eczema
Dermoscopy and UVFD in Differentiating Palmoplantar Psoriasis and Palmoplantar Eczema
Palmoplantar psoriasis and palmoplantar eczema are chronic inflammatory skin diseases that may show similar findings on the palms and soles, such as redness, scaling, thickening of the skin, fissures, itching, and burning.
- Trial name
- NCT07626697
- Where
- Turkey (Türkiye)
- Volunteers
- 81 people
- Sponsor
- Istanbul Training and Research Hospital
Palmoplantar Pustulosis
Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).
- Trial name
- NCT05174065
- Testing
- Apremilast
- Where
- 40 sites in Japan
- Volunteers
- 176 people
- Sponsor
- Amgen
Palmoplantar Pustulosis (PPP)
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16.
- Trial name
- NCT04015518
- Testing
- Spesolimab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 152 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis
The goal of this clinical trial is to investigate the efficacy and safety of Deucravacitinib in patients with moderate-to-severe palmoplantar pustulosis.
- Trial name
- NCT07000630
- Testing
- Deucravacitinib
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Peking University First Hospital
Palmoplantar Psoriasis
Efficacy Study of TEPSO® Socks in Improving Palmoplantar Psoriasis
The purpose of this study is to evaluate the efficacy of a special sock, manufactured using TEPSO®, compared to a normal cotton sock in the prognosis of symmetrical palmoplantar psoriasis present for at least one year.
- Trial name
- NCT01197976
- Testing
- TEPSO cloth, Standard cloth
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Lenzi Egisto S.P.A.
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L